New treatments for genital herpes

Current Opinion in Infectious Diseases

Volumn 15, Issue 1, 2002, Pages 49-55

  Snoeck, Robert ^a   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; PENCICLOVIR; TRIFLURIDINE; VALACICLOVIR;

DRUG ACTIVITY; DRUG BIOAVAILABILITY; GASTROINTESTINAL SYMPTOM; GENITAL HERPES; GENITAL ULCER; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; INCIDENCE; KIDNEY DISEASE; METABOLIC DISORDER; REVIEW; SEXUALLY TRANSMITTED DISEASE;

EID: 0036152989     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200202000-00009     Document Type: Review

References (70)

1. Herpes simplex virus-2 infection: An emerging disease?
2. A prospective study of new infections with herpes simplex virus type 1 and type 2
3. Genital herpes and public health. Addressing a global problem
4. Herpes simplex virus type 1 as a cause of genital herpes: Impact on surveillance and prevention
5. Herpes simplex virus infections
6. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States
7. Herpes simplex virus type 2 in the United States, 1976 to 1994
8. Current recommendations for the treatment of genital herpes
9. The heterogeneous clinical spectrum of genital herpes
10. A model of the transmission and control of genital herpes
11. Herpes simplex virus: The importance of asymptomatic shedding
12. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons
13. The importance of diagnosing genital herpes
14. Diagnosing genital ulcer disease in a clinic for sexually transmitted diseases in Amsterdam, The Netherlands
15. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities
16. The clinical manifestations and treatment of sexually transmitted diseases in human immunodeficiency virus-positive men
17. Recurrent lumbosacral herpes simplex in the bedridden hospitalized patient
18. Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding
19. Neonatal herpes prevention: A minor public health problem in some communities
20. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine
21. Antiviral therapy of herpes simplex and varicella-zoster virus infections
22. Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene
23. Nucleosides and foscarnet: Mechanisms
24. Foscarnet: A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections
25. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections
26. Comparative activity of various compounds against clinical strains of herpes simplex virus
27. Efficacy of (S)-2-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine in various models of herpes simplex virus infection in mice
28. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS
29. A new topical treatment for resistant herpes simplex infections
30. Successful treatment of progressive mucocutaneous infection due to acydovir- and foscarnet-resistant herpes simplex virus with (S-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC)
31. Susceptibility to acyclovir of herpes simplex virus isolates obtained between 1977 and 1996 in Japan
32. Efficacy of topical acyclovir monophosphate, acyclovir, or penciclovir in orofacial HSV-1 infections of mice and genital HSV-2 infections in guinea pigs
33. Current and potential therapies for the treatment of herpesvirus infections
34. Molecular targets for antiviral agents
35. The herpesvirus proteases as targets for antiviral chemotherapy
36. Inhibition of herpes proteases and antiviral activity of 2-substituted thieno[2,3-d]oxazinones
37. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex
38. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo
39. Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: Selection and characterization of mutant isolates
40. Herpes simplex virus type 1 uracil-DNA glycosytase: Isolation and selective inhibition by novel uracil derivatives
41. Molecular modeling and synthesis of inhibitors of herpes simplex virus type 1 uracil-DNA glycosylase
42. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product
43. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: Novel antiviral mechanism of 5,6-dichloro-2-(isopropylamino)-1-beta-I-ribofuranosyl-1H-benzimidazole
44. Specific inhibitors of herpes simplex virus thymidine kinase diminish reactivation of latent virus from explanted murine ganglia
45. Synthesis, properties, and pharmacokinetic studies of N2-phenylguanine derivatives as inhibitors of herpes simplex virus thymidine kinase
46. Some 6-aza-5-substituted-2G′-deoxyuridines show potent and selective inhibition of herpes simplex virus type 1 thymidine kinase
47. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification
48. Immunomodulating and antiviral activities of the imidazoquinoline S-28463
49. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment
50. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: A pilot study
51. Prospects for control of herpes simplex virus disease through immunization
52. Herpes simplex virus vaccines
53. Herpesvirus vaccines: Development, controversies, and applications
54. Mice genetic immunization with plasmid DNA encoding a secreted form of HSV-1 gB induces a protective immune response against herpes simplex virus type 1 infection
55. Therapeutic vaccination against HSV-2: Influence of vaccine formulation on immune responses and protection in mice
56. A comparison of oral and parenteral routes for therapeutic vaccination with HSV-2 ISCOMs in mice; cytokine profiles, antibody responses and protection
57. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs
58. Superiority of intramuscular route and full length glycoprotein D for DNA vaccination against herpes simplex 2: Enhancement of protection by the co-delivery of the GM-CSF gene
59. Herpes simplex virus DNA vaccine efficacy: Effect of glycoprotein D plasmid constructs
60. Why do we lack an effective vaccine against herpes simplex virus infections?
61. DNA vaccines for the prophylaxis and modulation of HSV infections
62. Immunization with a lymphocyte choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes
63. Bacterial CpG DNA activates immune cells to signal infectious danger
64. Dendritic cell vaccination protects mice against lethality caused by genital herpes simplex virus type 2 infection
65. Role of polymorphonuclear leukocytes in resolution of HSV-2 infection of the mouse vagina
66. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection
67. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial
68. The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model
69. Poly(sodium 4-styrene sulfonate): An effective candidate topical antimicrobial for the prevention of sexually transmitted diseases
70. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women